Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
Current Opinion in Oncology
|
January 27, 2025
Neoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint?
Michel Meyers, Oumnia Mouna, Mireille Langouo
Current Opinion in Oncology
|
February 18, 2026
Melanoma in adolescents and young adults: special considerations
Sofie Abboud, Luigi Romano, Mireille Langouo Fontsa
Seminars in Cancer Biology
|
March 26, 2018
The impact of tumor cell metabolism on T cell-mediated immune responses and immuno-metabolic biomarkers in cancer
Grégory Noël, Mireille Langouo Fontsa, Karen Willard-Gallo
Current Opinion in Oncology
|
January 27, 2025
Is there still a place for lymph node dissection for stage III melanoma since the approval of adjuvant therapy
Oumnia Mouna, Charlotte Hanssens, Michel Meyers, et al.
Expert Review of Clinical Immunology
|
July 15, 2024
Tumor-associated tertiary lymphoid structures in cancer: implications for immunotherapy
Mireille Langouo Fontsa, Francine Padonou, Karen Willard-Gallo
Current Opinion in Oncology
|
August 9, 2022
Biomarkers and immunotherapy: where are we?
Mireille Langouo Fontsa, Francine Padonou, Karen Willard-Gallo
Case Reports in Oncology
|
October 30, 2023
Trocar Site Recurrence after Laparoscopic Cholecystectomy for Unsuspected Isolated Gallbladder Metastasis of Melanoma: A Case Report and Review of the Literature
Céline Sergeant, Joseph Kerger, Annie Drowart, et al.
International Journal of Oncology
|
November 22, 2024
[Retracted] Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: A rationale to combine targeted drugs based on protein expression inhibition profiles
Philippe G Aftimos, Murielle Wiedig, Mireille Langouo Fontsa, et al.
International Journal of Oncology
|
July 10, 2013
Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: a rationale to combine targeted drugs based on protein expression inhibition profiles
Philippe G Aftimos, Murielle Wiedig, Mireille Langouo Fontsa, et al.
Targeted Oncology
|
September 14, 2022
Thromboembolism and Immune Checkpoint Blockade in Cancer Patients: An Old Foe for New Research
Mireille Langouo Fontsa, Marco Maria Aiello, Edoardo Migliori, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
Current Opinion in Oncology
|
January 27, 2025
Neoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint?
Michel Meyers, Oumnia Mouna, Mireille Langouo
Current Opinion in Oncology
|
February 18, 2026
Melanoma in adolescents and young adults: special considerations
Sofie Abboud, Luigi Romano, Mireille Langouo Fontsa
Seminars in Cancer Biology
|
March 26, 2018
The impact of tumor cell metabolism on T cell-mediated immune responses and immuno-metabolic biomarkers in cancer
Grégory Noël, Mireille Langouo Fontsa, Karen Willard-Gallo
Current Opinion in Oncology
|
January 27, 2025
Is there still a place for lymph node dissection for stage III melanoma since the approval of adjuvant therapy
Oumnia Mouna, Charlotte Hanssens, Michel Meyers, et al.
Expert Review of Clinical Immunology
|
July 15, 2024
Tumor-associated tertiary lymphoid structures in cancer: implications for immunotherapy
Mireille Langouo Fontsa, Francine Padonou, Karen Willard-Gallo
Current Opinion in Oncology
|
August 9, 2022
Biomarkers and immunotherapy: where are we?
Mireille Langouo Fontsa, Francine Padonou, Karen Willard-Gallo
Case Reports in Oncology
|
October 30, 2023
Trocar Site Recurrence after Laparoscopic Cholecystectomy for Unsuspected Isolated Gallbladder Metastasis of Melanoma: A Case Report and Review of the Literature
Céline Sergeant, Joseph Kerger, Annie Drowart, et al.
International Journal of Oncology
|
November 22, 2024
[Retracted] Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: A rationale to combine targeted drugs based on protein expression inhibition profiles
Philippe G Aftimos, Murielle Wiedig, Mireille Langouo Fontsa, et al.
International Journal of Oncology
|
July 10, 2013
Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: a rationale to combine targeted drugs based on protein expression inhibition profiles
Philippe G Aftimos, Murielle Wiedig, Mireille Langouo Fontsa, et al.
Targeted Oncology
|
September 14, 2022
Thromboembolism and Immune Checkpoint Blockade in Cancer Patients: An Old Foe for New Research
Mireille Langouo Fontsa, Marco Maria Aiello, Edoardo Migliori, et al.
Page
of 2